Literatur

1. Byrd JC et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-23.

2. Brown J et al. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2014, Abstract #3331.

3. Barrientos JC et al. Hematologic and immunologic function and patient well-being for the phase III RESONATE™ study of ibrutinibi vs ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2014, Abstract #4696